1. Introduction
===============

Autism spectrum disorder (ASD) is a heterogeneous set of neurodevelopmental diseases, characterized by deficits in social communication and verbal/nonverbal interaction, as well as restricted and repetitive patterns of interests and behaviors. It has a high prevalence of approximately 0.3% to 1.2%, with 3 main subtypes of autistic disorder, Asperger disorder and pervasive developmental disorder-not otherwise specified (PDD-NOS).^\[[@R1]\]^ Despite of onsite before 3 years old, most children are diagnosed with ASD after 4 years old.^\[[@R2]\]^ Early intensive behavioral interventions could improve the outcomes (e.g., language skills, cognitive performance, and adaptive behavior skills) in some young children with ASD.^\[[@R3]\]^ Thus, it has a critical need in clinical practice to increase the diagnostic accuracy for ASD.

As functional RNA molecules, non-coding RNAs (ncRNAs) are transcribed from DNA but not translated into proteins, including the types of long non-coding RNA (lncRNA), pseudogene, small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), ribosomal RNA (rRNA), miscellaneous RNA (miscRNA), and so on. ncRNAs have been reported in the pathogenesis of ASD, and aberrant expression of ncRNAs was detected in peripheral blood of ASD patients.^\[[@R4],[@R5]\]^ With great advances in genetic detection, gene expression profiles are available to identify novel and robust biomarkers. In this study, we obtain the ncRNA expression profiles through microarray probe re-annotation, and identify and validate a blood ncRNA signature for the diagnosis of ASD.

2. Methods
==========

2.1. Data preparation
---------------------

The database of Gene Expression Omnibus (GEO) (<http://www.ncbi.nlm.nih.gov/geo/>) was a public functional genomics data repository of array- and sequence-based data, and users could query and download experiments and curated gene expression profiles. In this database, we searched ASD-related datasets of gene expression profiles from inception to June 2019, using the key words including: ("autism spectrum disorder" OR "Asperger" OR "autis∗" OR "pervasive developmental disorder" OR "childhood disintegrative disorder"). Datasets were included if meeting the following criteria: detected blood gene expression profiles (probe-tabulated) of both ASD cases and healthy controls (HC); availability of clinical data and corresponding sequences of the microarray probes; the sample size was large enough. Then, the tab-delimited expression value-matrix table was downloaded and log~2~-transformed. This study was approved by the ethnic committee of Puren Hospital Affiliated to Wuhan University of Science and Technology.

2.2. Probe re-annotation
------------------------

First, we obtained the microarray probe sequences from the Affymetrix product website ([http://www.affymetrix.com](http://www.affymetrix.com/)), as well as the human genome sequences (GRCh38.p12) and comprehensive gene annotation from the GENCODE database ([https://www.gencodegenes.org](https://www.gencodegenes.org/)).^\[[@R6]\]^ Then, the probe sequences were aligned to the human genome sequences, using the software of hierarchical indexing for spliced alignment of transcripts (HISAT). No mismatches between probe sequence and reference sequence were allowed. Alignments were stored in SAM format where all alternative best hits were included. Among the successful alignments to the reference genome, we only included the transcripts with at least 1 alignment, each of which was also matched to only 1 transcript. When multiple probes matched to an identical gene, the average expression value across these probes was calculated to represent the corresponded gene. ncRNA expression profiles were extracted after excluding protein-coding RNAs (protein-coding and nonsense mediated decay) according to the RNA types.

2.3. ncRNA signature construction, evaluation, and validation
-------------------------------------------------------------

The samples were randomly divided into the training set and validation set according to the ratio of 6:4. In the training set, a least absolute shrinkage and selection operator (LASSO) penalized generalized linear model was adopted to identify significant ncRNAs.^\[[@R7],[@R8]\]^ The penalty parameter was estimated by 10-fold cross-validation at 1 standard error (SE) beyond the minimum partial likelihood deviance. Then, the coefficients of significant ncRNAs in the model were extracted to calculate a diagnostic score for each sample in the training set, validation set, and the overall. In receiver operating characteristic (ROC) curve analysis, area under ROC curve (AUC) was calculated to evaluate the diagnostic ability of the signature. Moreover, subgroup analysis was conducted on sex, age, and disease subtypes to assess the diagnostic stability of the signature, and DeLong test for 2 ROC curves was performed to investigate the difference between subgroups. Finally, we also compared the ncRNA signature with a 55-gene signature which derived from the same dataset.^\[[@R9]\]^

2.4. External validation
------------------------

The blood samples of 23 ASD and 23 age- and sex-matched controls were obtained in Puren Hospital from September 2015 to July 2017. Written informed consent was provided before sample collection, and the present study protocol was approved by the ethnic committee of Puren Hospital. Then, total RNA was extracted using TRIzol reagent (Invitrogen, Waltham, MA, USA), and stored at −80°C. The RNA concentration and purity were measured by the NanoDrop spectrophotometer (Thermo Fisher, Waltham, MA, USA). Total RNA was synthesized into first-strand cDNA using fluorescent-labeled dNTPs (Thermo Fisher, Waltham, MA, USA), before hybridization with a customized microarray which tailed and fixed 20 ncRNA probes (CapitalBio, China). The probe sequences were as follows:

1.  RNU1-16P: GGGACTATGTTCGTGTTCTCTCCTG

2.  RNU6-258P: AAGTCGTGAAATAGTCCATATGTTA

3.  RNU6-485P: CCCTGTGCAAGGATGATATGCAAAT

4.  RNU6-549P: GCTCACTTCAGTGGTACATATACTA

5.  RNVU1-15: GAACTCGACTGCATAACTTGTGATA

6.  RNA5SP160: CTATGGCCATAAAACCCTGAACTTG

7.  IGHV3-47: TCTCCAGAGACAACGCCAAGAAGTC

8.  TUBB2BP1: CATGCCCTCACCCAAGGTGTCAGAC

9.  CHST9-AS1: GGAAGTCTTCAGTATCTGTACAACT

10. AC074183.2: TGCCCAGGAGAAAGGCTGAAGGACA

11. AC136940.3: TTAGATTACGCTTGGCTTCTTTTGA

12. RP4-646B12.2: GAAAAAAGTGTGAATCAGTCACTAC

13. RP11-90M2.3: ATTGGTGGGTTTTGATGCCCAGTGA

14. RN7SL132P: AGCCCAGGAGCTCATAGTGCGCTAT

15. AC074117.12: CTGGCGTGGCAGAATACCTCTTTGA

16. AC069513.3: GCAGCGCCTCTTCCGACAGCCCCCA

17. RNY1P11: AAAGGGAGTGAGTTATCTCATTTGA

18. RP11-162A23.5: CCCACCTCCCCTACCAAAGCCCATA

19. MYCL2: GACCGCGACTCGTACCATCACTATT

20. RNU105B: AGGTCACTCTCTCCCCAGGCTGTGT

Finally, the ncRNA expression levels were detected by the GenePix microarray scanner (Axon Instrument, Union City, CA, USA), and a diagnostic score was calculated for each sample according to the signature formula.

2.5. Statistical analysis
-------------------------

All statistical analyses were conducted using R 3.6.0 software (The R Foundation, MA, USA). The generalized linear model was constructed with glmnet 2.0--18 package, and ROC curve analysis was performed with ROCR 1.0--7 package. A 2-sided *P* value \< .05 was considered statistically significant.

3. Results
==========

3.1. Characteristic of included dataset
---------------------------------------

The included microarray dataset of GSE18123 was based on the platform of GPL6244 (Affymetrix Human Gene 1.0 ST Array \[HuGene-1_0-st\]), with a total of 104 ASD (80 men \[76.9%\] and average age 8.1 years \[2--21\]) and 82 controls (48 men \[58.3%\] and average age 8.0 years \[2--22\]). The subtypes of autistic disorder, Asperger disorder, and PDD-NOS accounted for 39.4% (n = 41), 14.4% (n = 15), and 46.2% (n = 48) respectively. Then, 186 samples were randomly divided into the training set (n = 112) and validation set (n = 74).

3.2. Data preprocessing and sample clustering
---------------------------------------------

The GPL6244 platform contained 861,493 sequences (25 bases) aligned to 33,297 probes. After probe re-annotation, a total of 8089 RNAs (32 types) were identified with 18,329 specific probes, among which there were 4143 ncRNAs mapped to 10,258 probes.

Then, samples were clustered according to the distance in Pearson correlation matrices. When adopted the expression profiles of probes or genes, no outliers were detected (height \< 0.2).

3.3. Signature construction, evaluation, and validation
-------------------------------------------------------

One hundred eighty six blood samples in the microarray dataset were randomly divided into the training set (n = 112) and validation set (n = 72) according to the ratio of 6:4. In the training set, the LASSO penalized generalized linear model identified 20 significant ncRNAs, which demonstrated an obvious discrepancy between ASD and control samples (Table [1](#T1){ref-type="table"}). A diagnostic score was calculated for each sample according to the ncRNA expression levels weighted by their coefficients in the LASSO model.

###### 

Twenty non-coding RNAs in the blood diagnostic signature of autism spectrum disorder.
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Diagnostic score = AQP4-AS1∗(--0.169) + FTH1P2∗(--0.070) + FTH1P3∗0.261 + GMCL2∗(--0.097)  + HMGN2P11∗(--0.212) + IGHV3-47∗(--0.024) + MUC20-OT1∗(--0.143) + MYCLP1∗(--0.105) + POLR2KP2∗(--0.272) + RN7SL132P∗0.044 + RNA5SP160∗(--0.184) + RNU105B∗0.200 + RNU1-16P∗0.040 + RNU6-258P∗0.080 + RNU6-485P∗(--0.078) + RNU6-549P∗0.119 + RNVU1-15∗0.114 + RNY1P11∗(--0.160) +  RPS26P39∗(--0.083) + TUBB2BP1∗(--0.075)

The score displayed an excellent diagnostic ability for ASD in the training set (AUC = 0.96), validation set (AUC = 0.97), and the overall (AUC = 0.96) (Fig. [1](#F1){ref-type="fig"}). No significant difference was detected between the women and men in the training set (AUC: 0.96 vs 0.97, *P* = .890), validation set (AUC: 0.96 vs 1.00, *P* = .205), and the overall (AUC: 0.95 vs 0.98, *P* = .231) (Fig. [2](#F2){ref-type="fig"}). It was also insignificant between the older and younger cases in the training set (AUC: 0.93 vs 0.99, *P* = .088), validation set (AUC: 0.99 vs 0.95, *P* = .366), and the overall (AUC: 0.95 vs 0.97, *P* = .337) (Fig. [3](#F3){ref-type="fig"}).
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As for disease subtypes, the score had a good power in diagnosing autistic disorder (AUC = 0.97 in training set, 0.98 in validation set, and 0.97 in the overall), PDD-NOS (AUC = 0.96 in training set, 0.96 in validation set, and 0.95 in the overall), and Asperger disorder (AUC = 0.87 in training set, 0.96 in validation set, and 0.91 in the overall) (Fig. [4](#F4){ref-type="fig"}). No significant difference was detected between the subtypes (*P* \> .05).

![Receiver operating characteristic (ROC) curve analysis of the diagnostic signature in the subgroups of different disease subtypes. AUC = area under ROC curve.](medi-99-e19484-g005){#F4}

3.4. External validation
------------------------

The blood samples were collected from 23 ASD patients (14 men \[60.9%\] and average age 8.0 years \[2--16\]), and 23 age- and sex-matched controls. According to the signature formula, the score displayed a good diagnostic ability for ASD (AUC = 0.96) (Fig. [5](#F5){ref-type="fig"}).
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3.5. Comparison with a 55-gene signature
----------------------------------------

The previously published 55-gene signature derived from the same dataset.^\[[@R9]\]^ In the training set, the 55-gene signature showed no obvious difference than the ncRNA signature (AUC: 0.96 vs 0.96, *P* = 1.000) (Fig. [6](#F6){ref-type="fig"}). In the validation set, the 55-gene signature displayed a poorer performance than the ncRNA signature (AUC: 0.71 vs 0.97, *P* \< .001). In general, the ncRNA signature showed a better diagnostic ability than the 55-gene signature (AUC: 0.96 vs 0.68, *P* \< .001).
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4. Discussion
=============

In this study, we adopted the methods of probe re-annotation and penalized generalized linear model to identify a novel and robust blood ncRNA signature in diagnosing ASD. The signature showed an excellent stability in the subgroup analyses of age, sex, and disease subtypes. It also displayed a higher diagnostic efficiency than the 55-gene signature.

The ncRNA signature consisted of 20 genes, covering 5 kinds of ncRNAs (lncRNA, pseudogene, miscRNA, rRNA, snoRNA, and snRNA). lncRNAs are untranslated RNA molecules with \>200 nucleotides in length, which perform a wide variety of functions and play an important role in the development of mental discords.^\[[@R10]\]^ AQP4-AS1 had a moderate to high expression in nervous system (brain, cortex, and cerebellum) (based on the GTEx database). In GWAS Catalog, AQP4-AS1 was associated with the human phenotypes of blood protein measurement, lobe attachment, breast carcinoma, hair color, and glomerular filtration rate. MUC20-OT1 was involved into the phenotypes of mean corpuscular hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, eosinophil count, iron biomarker measurement, and transferrin measurement.

Pseudogenes are gene copies that have lost the original coding ability, and they have been reported in the pathogenesis of ASD.^\[[@R11]\]^ IGHV3-47 was associated with the phenotype of blood protein measurement. FTH1P3 was involved into the progression and prognosis of multiple cancers.^\[[@R12],[@R13]\]^ GMCL2 was related with protein binding (GO:0005515). MYCLP1 was associated with the phenotype of alcoholic pancreatitis. POLR2KP2 had a moderate to high expression in nervous system (brain, cortex, and cerebellum). RPS26P39 was associated with the phenotypes of sleep duration, age at menopause, and neutropenia, response to gemcitabine, pancreatic carcinoma. TUBB2BP1 had a moderate to high expression in nervous system (brain, cortex, and cerebellum), which was related with the phenotypes of red blood cell distribution width, mean corpuscular hemoglobin, and Crohn disease.

Small ncRNAs are regarded as new class of biomarkers and potential therapeutic targets in neurodegenerative diseases.^\[[@R14]\]^ In the signature, snRNAs are most frequent. As the components of spliceosome, snRNAs are fairly conserved with a uridine-rich non-coding sequence of \<200nt, and involved into the splicing of precursor mRNA. RNU1-16P had a moderate to high expression in nervous system (brain, cortex, and cerebellum) and whole blood. RNU6-258P was related with intelligence.^\[[@R15]\]^ Compared with normally developed children, the intelligence development in ASD children was significantly delayed.^\[[@R16],[@R17]\]^ There were positive correlations between age and mean corpuscular volume, and red cell distribution width in ASD children, and 24.1% cases had iron deficiency and 15.5% had anemia.^\[[@R18]\]^ RNU6-549P was associated with the GWAS phenotypes of mathematical ability, self reported educational attainment, coronary artery disease, and factor VII activating protease measurement. Previous studies suggested impaired metacognitive monitoring, mathematics under-achievement, and educational needs in ASD.^\[[@R19]--[@R21]\]^ RNVU1-15 had a moderate to high expression in nervous system and whole blood. It was associated with U1 snRNP (GO:0005685), mRNA 5′-splice site recognition (GO:0000395), pre-mRNA 5′-splice site binding (GO:0030627). A growing number of alternative splicing regulators have been reported in relation with ASD.^\[[@R22],[@R23]\]^

The limitations in this study should be also acknowledged. First, the sample size is not as large as we expected. Second, the method of probe re-annotation could not cover all ncRNAs. In the future, a large-scale prospective designed study was needed to validate this ncRNA signature.

In conclusion, through probe re-annotation and penalized generalized linear model, we identified a novel and robust blood ncRNA signature in diagnosing ASD, which might help improve the diagnostic accuracy for ASD in clinical practice.
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